{"id":"tak-330","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3348923","moleculeType":"Small molecule","molecularWeight":"506.30"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The exact mechanism of action for TAK-330 has not been detailed in public sources, indicating it may interact with specific biological pathways relevant to its targeted therapeutic area.","oneSentence":"TAK-330 is an investigational drug with a mechanism that is not fully disclosed publicly.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:47.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05156983","phase":"PHASE3","title":"A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-24","conditions":"Coagulation Disorder","enrollment":328}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAK-330","genericName":"TAK-330","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}